OPCH · Insider Trading
Option Care Health, Inc. Common Stock
Every open-market purchase and sale reported by OPCH officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-08 | Prateek Bhatia | EVP Sp Sales & Solutions | A | +39,795 | — |
| 2026-05-22 | Eric Brandt | Director | A | +11,640 | +$58.75K |
| 2026-05-22 | Norman L. Wright | Director | A | +8,997 | — |
| 2026-05-22 | Barbara W. Bodem | Director | A | +8,997 | — |
| 2026-05-22 | Timothy P Sullivan | Director | A | +13,833 | +$107.50K |
| 2026-05-22 | R Carter Pate | Director | A | +8,997 | — |
| 2026-05-22 | Harry M Jansen Kraemer Jr | Director | A | +21,076 | +$268.52K |
| 2026-05-22 | Natasha Deckmann | Director | A | +9,841 | +$18.76K |
| 2026-05-22 | Elizabeth D Bierbower | Director | A | +8,997 | — |
| 2026-05-21 | Collin Smyser | GC & Corporate Secretary | MIXED | +452 | −$7.51K |
| 2026-05-07 | Timothy P Sullivan | Director | Buy | +24,154 | +$499.67K |
| 2026-05-05 | Harry M Jansen Kraemer Jr | Director | Buy | +36,610 | +$783.77K |
| 2026-05-04 | John Charles Rademacher | Chief Executive Officer | Buy | +12,500 | +$264.71K |
| 2026-05-04 | Meenal Sethna | Chief Financial Officer | Buy | +16,225 | +$327.07K |
| 2026-04-24 | Femi Adewunmi | Chief Medical Officer | F | −1,396 | −$39.62K |
| 2026-03-03 | Michael Bavaro | Chief Human Resources Officer | Sell | −6,000 | −$198.00K |
| 2026-03-03 | R Carter Pate | Director | Sell | −30,287 | −$970.62K |
| 2026-02-26 | Nicole Maggio | Chief Accounting Officer | F | −975 | −$32.97K |
| 2026-02-26 | Michael Bavaro | Chief Human Resources Officer | F | −1,354 | −$45.79K |
| 2026-02-26 | John Charles Rademacher | Chief Executive Officer | F | −11,050 | −$373.66K |
| 2026-02-26 | Femi Adewunmi | Chief Medical Officer | F | −1,627 | −$55.02K |
| 2026-02-26 | Collin Smyser | GC & Corporate Secretary | F | −2,210 | −$74.73K |
| 2026-02-26 | Christopher L. Grashoff | Chief Growth Officer | F | −1,980 | −$66.95K |
| 2026-02-26 | Luke Whitworth | Chief Operating Officer | F | −4,605 | −$155.72K |
| 2026-02-24 | Collin Smyser | GC & Corporate Secretary | F | −17,445 | −$622.61K |
| 2026-02-24 | John Charles Rademacher | Chief Executive Officer | MIXED | −137,355 | −$5.30M |
| 2026-02-24 | Luke Whitworth | Chief Operating Officer | F | −28,044 | −$1.00M |
| 2026-02-24 | Nicole Maggio | Chief Accounting Officer | F | −991 | −$35.37K |
| 2026-02-24 | Christopher L. Grashoff | Chief Growth Officer | F | −2,486 | −$88.73K |
| 2026-02-24 | Michael Bavaro | Chief Human Resources Officer | F | −13,399 | −$478.21K |
| 2026-02-19 | Collin Smyser | GC & Corporate Secretary | A | +15,213 | — |
| 2026-02-19 | Meenal Sethna | Chief Financial Officer | A | +27,045 | — |
| 2026-02-19 | Femi Adewunmi | Chief Medical Officer | A | +9,579 | — |
| 2026-02-19 | John Charles Rademacher | Chief Executive Officer | A | +78,876 | — |
| 2026-02-19 | Nicole Maggio | Chief Accounting Officer | MIXED | +3,979 | −$8.70K |
| 2026-02-19 | Michael Bavaro | Chief Human Resources Officer | MIXED | +9,028 | −$19.42K |
| 2026-02-19 | Christopher L. Grashoff | Chief Growth Officer | MIXED | +12,419 | −$9.13K |
| 2026-02-19 | Luke Whitworth | Chief Operating Officer | MIXED | +29,915 | −$17.90K |
| 2025-11-04 | Harry M Jansen Kraemer Jr | Director | Buy | +38,000 | +$987.39K |
| 2025-10-03 | Meenal Sethna | Chief Financial Officer | A | +55,067 | — |
| 2025-09-10 | Norman L. Wright | Director | Buy | +3,411 | +$99.98K |
| 2025-08-21 | David W Golding | Director | Buy | +1,000 | +$27.62K |
| 2025-08-21 | Timothy P Sullivan | Director | Buy | +20,000 | +$550.20K |
| 2025-08-21 | Harry M Jansen Kraemer Jr | Director | Buy | +36,000 | +$977.28K |
| 2025-08-21 | R Carter Pate | Director | Buy | +750 | +$20.39K |
| 2025-08-08 | Nicole Maggio | Chief Accounting Officer | A | +7,167 | — |
| 2025-05-21 | Collin Smyser | GC & Corporate Secretary | MIXED | +483 | −$354.49K |
| 2025-05-19 | Eric Brandt | Director | A | +5,034 | — |
| 2025-05-19 | Norman L. Wright | Director | A | +5,034 | — |
| 2025-05-19 | Barbara W. Bodem | Director | A | +5,034 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| John Charles Rademacher | Chief Executive Officer | 695,152 | $21.75M |
| Harry M Jansen Kraemer Jr | Director | 458,997 | $14.36M |
| Michael H. Shapiro | Chief Financial Officer | 311,933 | $9.76M |
| Luke Whitworth | Chief Operating Officer | 169,589 | $5.31M |
| David W Golding | Director | 116,525 | $3.65M |
| Meenal Sethna | Chief Financial Officer | 98,337 | $3.08M |
| Timothy P Sullivan | Director | 87,216 | $2.73M |
| Collin Smyser | GC & Corporate Secretary | 77,512 | $2.43M |
| Christopher L. Grashoff | Chief Growth Officer | 44,092 | $1.38M |
| Michael Bavaro | Chief Human Resources Officer | 33,249 | $1.04M |
| Elizabeth D Bierbower | Director | 32,871 | $1.03M |
| Natasha Deckmann | Director | 32,002 | $1.00M |
| Elizabeth Quadros Betten | Director | 29,216 | $914.17K |
| Nicole Maggio | Chief Accounting Officer | 28,489 | $891.42K |
| Femi Adewunmi | Chief Medical Officer | 25,314 | $792.08K |
| Norman L. Wright | Director | 24,498 | $766.54K |
| Eric Brandt | Director | 21,999 | $688.35K |
| Barbara W. Bodem | Director | 21,087 | $659.81K |
| R Carter Pate | Director | 20,620 | $645.20K |
| Prateek Bhatia | EVP Sp Sales & Solutions | 16,386 | $512.72K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the OPCH quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.